101 related articles for article (PubMed ID: 6603265)
1. Phase I study of pharmacological and immunological effects of human lymphoblastoid interferon given to patients with cancer.
Laszlo J; Huang AT; Brenckman WD; Jeffs C; Koren H; Cianciolo G; Metzgar R; Cashdollar W; Cox E; Buckley CE; Tso CY; Lucas VS
Cancer Res; 1983 Sep; 43(9):4458-66. PubMed ID: 6603265
[TBL] [Abstract][Full Text] [Related]
2. Extended phase I study of human beta-interferon in human cancer.
Abdi EA; Kamitomo VJ; McPherson TA; Konrad MW; Inoue M; Tan YH
Clin Invest Med; 1986; 9(1):33-40. PubMed ID: 3955919
[TBL] [Abstract][Full Text] [Related]
3. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
4. High-dose human lymphoblastoid interferon in metastatic colorectal cancer: clinical results and modification of biological responses.
Krown SE; Mintzer D; Cunningham-Rundles S; Niedzwiecki D; Krim M; Einzig AI; Gabrilove JL; Shurgot B; Gessula J
Cancer Treat Rep; 1987 Jan; 71(1):39-45. PubMed ID: 3791267
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
6. Human alpha-lymphoblastoid interferon. A phase I study including pharmacokinetics and effects on hematologic stem cells (CFU-GMs).
Sarna G; Figlin R; Bryson Y; Garratty E; Myers L; Le Fevre C; Mauritzon N; Cline M
Am J Clin Oncol; 1985 Oct; 8(5):406-12. PubMed ID: 4061375
[TBL] [Abstract][Full Text] [Related]
7. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients.
Koren HS; Brandt CP; Tso CY; Laszlo J
J Biol Response Mod; 1983; 2(2):151-65. PubMed ID: 6644332
[TBL] [Abstract][Full Text] [Related]
8. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
Ernstoff MS; Fusi S; Kirkwood JM
J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha therapy of renal cancer.
Neidhart JA; Gagen MM; Young D; Tuttle R; Melink TJ; Ziccarrelli A; Kisner D
Cancer Res; 1984 Sep; 44(9):4140-3. PubMed ID: 6378379
[TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
11. Immunological effects of recombinant interferon-alpha 2 in cancer patients.
Hengst JC; Kempf RA; Kan-Mitchell J; Pham AT; Grunberg SM; Kortes VL; Mitchell MS
J Biol Response Mod; 1983; 2(6):516-27. PubMed ID: 6663321
[TBL] [Abstract][Full Text] [Related]
12. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
13. Effects of recombinant interferon-alpha on immune function in cancer patients.
Maluish AE; Leavitt R; Sherwin SA; Oldham RK; Herberman RB
J Biol Response Mod; 1983; 2(5):470-81. PubMed ID: 6358423
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the immunological and toxicological properties of MVE-2 in phase I trials.
Rinehart JJ; Young DC; Neidhart JA
Cancer Res; 1983 May; 43(5):2358-62. PubMed ID: 6831459
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of low doses of alpha interferon in patients with breast cancer.
Laszlo J; Hood L; Cox E; Goodwin B
J Biol Response Mod; 1986 Jun; 5(3):206-10. PubMed ID: 3723137
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of human leukocyte interferon in patients with advanced cancer.
Horning SJ; Levine JF; Meyer M; Merigan TC; Rosenberg SA
J Biol Response Mod; 1983; 2(1):47-56. PubMed ID: 6196450
[TBL] [Abstract][Full Text] [Related]
17. [Phase I study of recombinant human interferon alpha A (Ro 22-8181) in patients with malignant tumors].
Taguchi T
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):456-64. PubMed ID: 4004281
[TBL] [Abstract][Full Text] [Related]
18. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of Wellferon (human lymphoblastoid alpha-interferon) as cancer therapy: clinical results.
Sarna G; Figlin R; McCarthy S
J Biol Response Mod; 1983; 2(2):187-95. PubMed ID: 6644335
[TBL] [Abstract][Full Text] [Related]
20. [Phase-1 study of the tolerance for increasing doses of recombinant human alpha 2 interferon in patients with advanced cancer].
Bretaudeau B; Palangie T; Giralt E; Jouve M; Pouillart P; Falcoff E; Fridman WH; Magdelenat H; Derstepani L; Laurent T
Bull Cancer; 1984; 71(1):40-9. PubMed ID: 6713113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
